Home > Healthcare > Pharmaceuticals > Finished Drug Form > Retinal Biologics Market

Retinal Biologics Market Share

Report ID: GMI4429
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Retinal Biologics Market Share

The retinal biologics industry is characterized by the presence of leading pharmaceutical and biopharmaceutical companies. The key market players include F-Hoffman La Roche Ltd., Novartis AG, and AbbVie Inc. which are focused on developing improved treatments, such as longer-acting formulations and innovative therapies. Market players compete on factors like efficacy, safety, patient convenience, and cost-effectiveness.

Retinal Biologics Market Companies

Prominent players operating in the retinal biologics industry include:

AbbVie Inc.
Amgen Inc.
Janssen Pharmaceuticals (Johnson & Johnson)
F-Hoffman La Roche Ltd.
Oxurion NV
Novartis AG
MeiraGTx Limited
Regeneron Pharmaceuticals Inc.
OncoGene Pharmaceuticals
SemaThera Inc.

Authors: Mariam Faizullabhoy , Gauri Wani

Frequently Asked Questions (FAQ) :

The global retinal biologics market was valued at USD 23.4 billion in 2023 and is anticipated grow at 8.2% CAGR during 2024-2032, attributed to the increasing prevalence of retinal diseases, particularly age-related macular degeneration (AMD) and diabetic retinopathy.

The macular degeneration segment held 40.1% of the market share in 2023 owing to the growing elderly population globally.

North America retinal biologics market was valued at USD 9.7 billion and is predicted to grow at 8% CAGR during 2024-2032, attributed to the advanced healthcare infrastructure and high prevalence of retinal diseases.

AbbVie Inc., Amgen Inc., Janssen Pharmaceuticals (Johnson & Johnson), F-Hoffman La Roche Ltd., Oxurion NV, Novartis AG, MeiraGTx Limited, Regeneron Pharmaceuticals Inc., OncoGene Pharmaceuticals and SemaThera In